Real-World Use of Hypomethylating Agents (HMA)/Venetoclax Combinations in Patients with Myelodysplastic Neoplasms (MDS) in the Arabian Gulf Region

被引：0
|
作者：
Khadadah, Fatima [1 ]
Cherif, Honar [2 ]
El Omri, Halima [3 ]
Absi, Ahmed [4 ]
Merwass, Noor [5 ]
Abu Haleeqa, Mohamed I. [6 ]
Jaber, Waed [6 ]
Alhuraiji, Ahmad [7 ]
Pandita, Ramesh [1 ]
机构：
[1] Kuwait Canc control Ctr, Kuwait, Kuwait
[2] Natl Ctr Canc Care & Res, Hematol BMT, Doha, Qatar
[3] Hamad Univ, Ar Rayyan, Qatar
[4] Natl Guard Hlth Affairs, Princess Noorah Oncol Ctr, King Abdulaziz Med City Western Reg, Jeddah, Saudi Arabia
[5] Minist Natl Guard Hlth Affairs, Dept Adult Hematol & Stem Cell Transplantat, Princess Noorah Oncol Ctr, Jeddah, Saudi Arabia
[6] Sheikh Shakhbout Med Ctr, Abu Dhabi, U Arab Emirates
[7] Kuwait Canc Ctr, Shuwaikh, Kuwait
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181520
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Real-World Use of Hypomethylating Agents (HMA)/Venetoclax Combinations in Patients With Myelodysplastic Neoplasms (MDS) in the Arabian Gulf Region
    Khadadah, Fatima
    Cherif, Honar
    AlOmri, Halima
    Alhuraiji, Ahmad
    Pandita, Ramesh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S370 - S371
  • [2] Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts
    Gangat, Naseema
    McCullough, Kristen
    Johnson, Isla
    Al-Kali, Aref
    Begna, Kebede H.
    Patnaik, Mrinal M.
    Litzow, Mark R.
    Hogan, William
    Shah, Mithun
    Alkhateeb, Hassan
    Mangaonkar, Abhishek
    Foran, James M.
    Badar, Talha
    Palmer, Jeanne M.
    Sproat, Lisa
    Arana Yi, Cecilia Y.
    Pardanani, Animesh
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (06) : E214 - E216
  • [3] A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients
    Zhang, Ludan
    Ge, Rui
    Pan, Deng
    Yue, Pengjie
    Zhang, Jingwen
    Bian, Renjie
    Yan, Xiaojing
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [4] Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA)
    Nazha, Aziz
    Sekeres, Mikkael A.
    Garcia-Manero, Guillermo
    Barnard, John
    Al Ali, Najla H.
    Roboz, Gail J.
    Steensma, David P.
    DeZern, Amy E.
    Zimmerman, Cassie
    Jabbour, Elias
    Greenberg, Molly D.
    Lee, Sangmin
    List, Alan F.
    Kantarjian, Hagop M.
    Maciejewski, Jaroslaw P.
    Komrokji, Rami S.
    BLOOD, 2014, 124 (21)
  • [5] Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure
    Ball, Brian J.
    Famulare, Christopher A.
    Stein, Eytan M.
    Tallman, Martin S.
    Derkach, Andriy
    Roshal, Mikhail
    Gill, Saar, I
    Manning, Benjamin M.
    Koprivnikar, Jamie
    McCloskey, James
    Testi, Rebecca
    Prebet, Thomas
    Al Ali, Najla H.
    Padron, Eric
    Sallman, David A.
    Komrokji, Rami S.
    Goldberg, Aaron D.
    BLOOD ADVANCES, 2020, 4 (13) : 2866 - 2870
  • [6] Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience
    Azizi, Armon
    Ediriwickrema, Asiri
    Dutta, Ritika
    Patel, Shyam A.
    Shomali, William
    Medeiros, Bruno
    Iberri, David
    Gotlib, Jason
    Mannis, Gabriel
    Greenberg, Peter
    Majeti, Ravindra
    Zhang, Tian
    LEUKEMIA & LYMPHOMA, 2020, 61 (11) : 2700 - 2707
  • [7] Time toxicity for patients receiving oral versus parenteral hypomethylating agents for myelodysplastic syndromes/neoplasms (MDS).
    Epstein, Robert S.
    Zeidan, Amer Methqal
    Olopoenia, Abisola
    Costantino, Halley
    Modi, Kushal
    Salimi, Tehseen
    Washington, Terri
    Krenitsky, Joann
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium
    Jabbour, Elias
    Sasaki, Koji
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Steensma, David P.
    DeZern, Amy E.
    Gail, Roboz J.
    Daver, Naval G.
    Pemmaraju, Naveen
    Kadia, Tapan
    DiNardo, Courtney D.
    Wang, Xuemei
    Nogueras-Gonzalez, Graciela
    Borthakur, Gautam
    Estrov, Zeev
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
  • [9] Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series
    Badar, Talha
    Shah, Kashish J.
    El Kettani, Mobachir
    Foran, James M.
    Kharfan-Dabaja, Mohamed A.
    Murthy, Hemant S.
    Gangat, Naseema
    Al-Kali, Aref
    Shah, Mithun, V
    Alkhateeb, Hassan B.
    Saliba, Antoine N.
    Hogan, William J.
    Yi, Cecilia Y. Arana
    Sproat, Lisa
    Palmer, Jeanne
    Litzow, Mark R.
    Patnaik, Mrinal M.
    BLOOD, 2024, 144 : 1823 - 1824
  • [10] Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)
    Kewan, Tariq
    Bewersdorf, Jan Philipp
    Blaha, Ondrej
    Stahl, Maximilian
    Ali, Najla Hal
    DeZern, Amy E.
    Sekeres, Mikkael A.
    Carraway, Hetty E.
    Desai, Pinkal
    Griffiths, Elizabeth A.
    Stein, Eytan M.
    Brunner, Andrew M.
    Amaya, Maria L.
    Zeidner, Joshua F.
    Savona, Michael R.
    Stempel, Jessica M.
    Chandhok, Namrata Sonia
    Logothetis, Constantine
    Ramaswamy, Rahul
    Rose, Ameera
    Roboz, Gail J.
    Rolles, Benjamin
    Wang, Eunice S.
    Harris, Amyah C.
    Shallis, Rory M.
    Xie, Zhuoer
    Padron, Eric
    Maciejewski, Jaroslaw P.
    Sallman, David A.
    Della Porta, Matteo Giovanni
    Komrokji, Rami S.
    Zeidan, Amer M.
    BLOOD, 2023, 142
12345